Back to search results

Extended-Release Buprenorphine for Opioid Use Disorder on a Mobile Pharmacy Clinic

This study is looking at how well a monthly or weekly shot of extended-release buprenorphine (BRIXADI) works for people with opioid use disorder (OUD) when given through a mobile pharmacy clinic. You might be able to join if you are 18 or older, have moderate-to-severe OUD, and plan to stay in the area during the study. The main goal is to see if people stay on the BRIXADI treatment for six months. The study is currently unclear on its recruitment status and plans to enroll about 60 people.

Study design
This is a prospective cohort study, meaning participants will be followed over time. About 60 people are planned to be enrolled.
What's involved
You would receive weekly or monthly injections of BRIXADI for six months. Medical visit data and medical record data will be collected during this time.
Compensation
You will have access to free medication for 6 months.
Follow-up
Medical visit data will be collected for 6 months, and the primary endpoint is measured at Month 6.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07176351

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

Not Yet Recruiting
PHASE4Ages 18+InterventionalTreatment
Yale University
~60 participants
Updated 2026-07-31 on ClinicalTrials.gov
What's tested:Buprenorphine

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Retention of XR-B at month 6
Measured over Month 6

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

1 sites across 1 states
Connecticut1

Study leadership

  • Sandra Springer, MD · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Sandra Springer, MD
[email protected]
203-687-6680
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to provide written informed consent in English or Spanish
Current or history of DSM-5 moderate-to-severe OUD per Rapid Opioid Use Disorder Assessment (ROUDA)
Not planning to move out of state or to new location during study enrollment.

Exclusion

Medical or psychiatric disorders making participation unsafe or regular follow-up unlikely, (such as suicidal ideation or pre-existing moderate to severe hepatic impairment)
Persons who are pregnancy
People who show violent or threatening behavior toward staff and/or others
Allergy, hypersensitivity, or medical contraindication to medication (the BRIXADI needle cap is synthetically derived from natural rubber latex which may cause allergic reactions in persons with latex-sensitivity)

What this trial measures

  • Retention of XR-B at month 6Month 6

    Proportion of participants that were retained on 6 months of XR-B injections.